Analysts expect PerkinElmer, Inc. (NYSE:PKI) to report $2.41 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for PerkinElmer’s earnings, with estimates ranging from $2.34 to $2.49. PerkinElmer reported earnings per share of $1.57 during the same quarter last year, which suggests a positive year over year growth rate of 53.5%. The firm is expected to issue its next quarterly earnings report after the market closes on Wednesday, July 28th.
According to Zacks, analysts expect that PerkinElmer will report full-year earnings of $9.50 per share for the current financial year, with EPS estimates ranging from $9.35 to $9.80. For the next fiscal year, analysts expect that the business will report earnings of $5.91 per share, with EPS estimates ranging from $5.70 to $6.36. Zacks’ EPS calculations are an average based on a survey of research analysts that cover PerkinElmer.
PerkinElmer (NYSE:PKI) last released its quarterly earnings data on Tuesday, May 4th. The medical research company reported $3.72 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.69. PerkinElmer had a net margin of 24.19% and a return on equity of 36.60%. The firm had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.18 billion. During the same period in the previous year, the company earned $0.67 earnings per share. The firm’s quarterly revenue was up 100.4% on a year-over-year basis.
In related news, insider Andrew Okun sold 2,370 shares of the company’s stock in a transaction on Thursday, June 10th. The shares were sold at an average price of $145.71, for a total transaction of $345,332.70. Also, Director Sylvie Gregoire sold 5,000 shares of the company’s stock in a transaction on Tuesday, July 6th. The stock was sold at an average price of $155.57, for a total transaction of $777,850.00. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company’s stock.
Several large investors have recently modified their holdings of the stock. Select Equity Group L.P. boosted its position in shares of PerkinElmer by 11.0% during the fourth quarter. Select Equity Group L.P. now owns 10,326,036 shares of the medical research company’s stock worth $1,481,786,000 after acquiring an additional 1,019,219 shares during the last quarter. BlackRock Inc. boosted its position in shares of PerkinElmer by 7.6% during the first quarter. BlackRock Inc. now owns 7,904,659 shares of the medical research company’s stock worth $1,014,091,000 after acquiring an additional 556,072 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of PerkinElmer by 60.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,312,457 shares of the medical research company’s stock worth $681,535,000 after acquiring an additional 1,992,799 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of PerkinElmer by 6.6% during the first quarter. Massachusetts Financial Services Co. MA now owns 4,414,201 shares of the medical research company’s stock worth $566,298,000 after acquiring an additional 271,538 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of PerkinElmer by 0.6% during the first quarter. Geode Capital Management LLC now owns 1,972,555 shares of the medical research company’s stock worth $252,412,000 after acquiring an additional 11,683 shares during the last quarter. Hedge funds and other institutional investors own 91.72% of the company’s stock.
PKI stock traded up $3.45 during midday trading on Thursday, reaching $160.08. 16,059 shares of the company’s stock traded hands, compared to its average volume of 603,770. PerkinElmer has a 52-week low of $109.54 and a 52-week high of $162.70. The company has a market cap of $17.94 billion, a PE ratio of 16.74, a P/E/G ratio of 0.43 and a beta of 1.11. The company has a current ratio of 1.76, a quick ratio of 1.41 and a debt-to-equity ratio of 0.55. The stock’s 50-day moving average is $148.68.
The company also recently declared a quarterly dividend, which will be paid on Friday, August 6th. Shareholders of record on Friday, July 16th will be given a $0.07 dividend. The ex-dividend date is Thursday, July 15th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.17%. PerkinElmer’s payout ratio is currently 3.37%.
PerkinElmer Company Profile
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Featured Story: How does a 12b-1 fee affect fund performance?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.